Drug Information

Drug General Information
Drug ID
D00KGB
Former ID
DNCL002760
Drug Name
Abagovomab
Drug Type
Monoclonal antibody
Indication Ovarian cancer [ICD9: 183; ICD10:C56] Phase 2/3 [521945], [543020]
Company
Menarini
CAS Number
CAS 792921-10-9
Target and Pathway
Target(s) Mucin 16 Target Info [531365]
References
Ref 521945ClinicalTrials.gov (NCT00418574) Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients. U.S. National Institutes of Health.
Ref 543020(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8265).
Ref 531365Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy. 2011 Feb;3(2):153-62.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.